AU734737B2

AU734737B2 - Plaque-inhibiting oral compositions

Info

Publication number: AU734737B2
Application number: AU96213/98A
Authority: AU
Inventors: Rie Tsuchiya
Original assignee: Novozymes AS
Current assignee: Novozymes AS
Priority date: 1997-10-17
Filing date: 1998-10-16
Publication date: 2001-06-21
Anticipated expiration: 2018-10-16
Also published as: AU9621398A; WO1999020239A1; EP1023037A1; CA2305804A1; CN1275906A; JP2001520179A

Description

WO 99/20239 PCT/DK98/00452 WO 9920239PCT/DK98/0452 1 TITLE: Plaque-inhibiting oral compositions FIELD OF THE INVENTION The present invention relates to oral compositions comprising plaque-inhibiting or plaque-removing enzymes and to a method for inhibiting plaque formation or removing plaque using such oral compositions.

BACKGROUND OF THE INVENTION Dental plaque is a mixture of bacteria, epithelial cells, leukocytes, macrophages and other oral exudates that forms on the surface of unclean teeth. The bacteria produce highly branched polysaccharides which together with microorganisms from the oral cavity form an adhesive matrix for the continued proliferation of plaque. Left untreated, the formation of dental plaque will eventually lead to dental caries, gingival inflammation, periodontal disease, and eventually tooth loss. As plaque continues to accumulate, rockhard white or yellowish deposits arise. These deposits are called calcified plaque, calculus or tartar, and are formed in the saliva from plaque and minerals, in particular calcium.

Oral polysaccharides are produced from sucrose introduced into the mouth, e.g.

as a food or beverage constituent, by the action of cariogenic microorganisms such as Streptococcus mutans or Streptococcus sanguis growing in the oral cavity. These oral polysaccharides comprise water-soluble dextran having primarily a-1,6 glucosidic linkages, and a major component of water-insoluble extracellular polysaccharides called "mutan" comprised of a backbone with a-1,3-glycosidic linkages and branches with a- 1,6-glycosidic linkages. Mutan binds to hydroxyapatite (constituting the hard outer porous layer of the teeth) and to acceptor proteins on the cell surface of said cariogenic bacteria adhering to the teeth surface.

Numerous attempts have been made to combat this process by either eliminating the plaque or by altering the environment by changing the composition of the plaque, and many toothpastes and other oral care compositions have, with varying success, aimed at removing or inhibiting plaque. The goal of effectively inhibiting plaque in particular has remained elusive, however, and the need remains for oral care compositions that in normal use are effective at inhibiting plaque formation and the accompanying dental diseases that can result from plaque formation.

WO 99/20239 PCT/DK98/00452 2 WO 97/06775 discloses oral compositions comprising an oxidoreductase, and optionally a dextranase and/or a mutanase, for bleaching of teeth, but no plaqueinhibiting or plaque-removing effects of such compositions are described or suggested.

To prevent the formation of dental caries, plaque and tartar, it has been suggested to add a dextranase and/or a mutanase and/or other enzymes to oral care compositions and products.

JP patent publication 8012544 (Lion) describes a plaque preventing effect of dextranase, mutanase and triclosan and/or biosol.

US patent No. 4,353,891 (Guggenheim et al.) concerns plaque removal using mutanase from Trichoderma harzianum CBS 243.71 to degrade mutan synthesized by cultivating Streptococcus mutans strain CBS 350.71 identifiable as OMZ 176. It is stated that the critical ingredient in dental plaque is a water-insoluble polysaccharide with a-1,3-glucosidic bonds and that such polysaccharide material termed mutan is not attacked by dextranase.

Guggenheim et al. (1972), Caries Res. 6, p. 289-297, disclose that the extent of dental plaque of rats is not significantly affected by the simultaneous use of a dextranase and a 1,3-glucanase (mutanase).

Hare et al. (1978), Carbohydrate Research 66, p. 245-264, found that a synergistic effect is obtained when hydrolysing and solubilizing oral glucans with a bacterial dextranase in combination with bacterial a-1,3 glucanase from Cladosporium resinae.

US patent No. 4,438,093 (The Research Foundation for Microbial diseases of Osaka) describes oral compositions comprising a dextranase and a a-1,3-glucanase (mutanase), both being present in an amount of 0.5 to 100 enzyme units per gram of said oral composition, in an enzyme unit ratio of 1:2 to 2:1. Said dextranase is derived from a bacteria within the genus Corynbacterium and said a-1,3-glucanase is derived from a bacteria within the genus Pseudomonas.

GB 2,206,585 (Dental Chem Co. Ltd.) describes a tooth-cleaning agent containing hydroxyapatite as a polishing agent, with a laevanase, dextranase and mutanase immobilized on the hydroxyapatite.

US patent No. 5,145,665 (Henkel) discloses a composition for the care of the mouth and teeth comprising a dextranase and/or a 1,3-glucanase for cleaving polysaccharides in the mouth.

FR 2,651,433 (DANA) concerns dentifrice products containing a dextranase to act on recent plaque, a mutanase to act on old and insoluble plaque, and a mixture of other enzymes having bactericidal action.

US patent No. 5,320,830 (Proctor Gamble) describes toothpaste compositions for the reduction of plaque and gingivitis comprising a) a surfactant, b) an enzyme, c) a chelating agent, d) a fluoride source, e) a silica abrasive and f) a carrier. The enzyme is an endoglucanase, papain, a dextranase and/or a mutanase.

It has now surprisingly been found that oral care compositions comprising one or more starch-hydrolysing or starch-modifying enzymes are effective for inhibiting/ preventing dental plaque formation and/or for removing plaque.

Summary of the Invention The object of the present invention is thus to provide oral compositions that are effective for inhibiting/preventing plaque formation and for removing plaque, as well as a method for inhibiting plaque formation or for removing plaque.

According to one embodiment of this invention, there is provided an oral care composition comprising a plaque-inhibiting and/or plaque-removing effective amount of lE* at least one starch-modifying enzyme selected from the group of enzymes within E.C. 2.4.1.

According to another embodiment of this invention, there is provided the use of at least one starch-modifying enzyme selected from the group of enzymes within E.C. 2.4.1.

for the preparation of an oral care composition for the inhibition of plaque formation and/or removal of plaque.

According to a further embodiment of this invention, there is provided the use of at least one starch-modifying enzyme selected from the group of enzymes within E.C. 2.4.1.

25 in combination with at least one starch-hydrolysing enzyme for the preparation of an oral Scare composition for the inhibition of plaque formation and/or removal of plaque.

i S• Detailed Description of the Invention The term "starch-hydrolysing enzyme" in the context of the present application refers to any enzyme, such as an ot-amylase which functions to hydrolyse linkages in starch.

[R:\LIBXX] 2 016spec.doc:gcc WO 99/20239 PCT/DK98/00452 4 The term "starch-modifying enzymes" used in the context of the invention refers to the group of enzymes within E.C. and includes in particular transglycosidases 2.4.1.18) and CGTases 2.4.1.19).

The inventors have found that dental plaque can be inhibited/prevented or removed by the use of at least one starch-hydrolysing enzyme and/or at least one starch-modifying enzyme. Said effect of such enzymes has not been foreseen before.

In the first aspect the invention relates to an oral care composition comprising a plaque-inhibiting and/or plaque-removing effective amount of at least one starchhydrolysing enzyme and/or at least one starch-modifying enzyme.

In an embodiment of the invention the starch-modifying enzyme is a CGTase 2.4.1.19) or a transglucosidase (2.4.1.18).

When the starch-modifying enzyme is a CGTase, it may be derived from a strain of Bacillus autolyticus, a strain of Bacillus cereus, a strain of Bacillus circulans, a strain of Bacillus circulans var. alkalophilus, a strain of Bacillus coagulans, a strain of Bacillus firmus, a strain of Bacillus halophilus, a strain of Bacillus macerans, a strain of Bacillus megaterium, a strain of Bacillus ohbensis, a strain of Bacillus stearothermophilus, a strain of Bacillus subtilis, a strain of Klebsiella pneumoniae, a strain of Thermoanaerobacter sp., a strain of Thermoanaerobacter ethanolicus, a strain of Thermoanaerobacter finnii, a strain of Clostridium thermoamylolyticum, a strain of Clostridium thermosaccharolyticum, or a strain of Thermoanaerobacterium thermosulfurigenes.

When the starch-modifying enzyme is a transglucosidase, it may be derived from Aspergillus niger, e.g. the product sold by Amamo Pharmaceutical Co., Japan.

In another embodiment of the invention the oral care composition comprises a starch-hydrolysing enzyme.

This will typically be an a-amylase, such as a bacterial a-amylase, such as BAN'" or Maltogenase" (both available from Novo Nordisk), or an a-amylase derived from Bacillus subtilis; an a-amylase derived from Bacillus amyloliquefaciens; an a-amylase derived from Bacillus stearothermophilus; an a-amylase derived from Aspergillus oryzae; or an a-amylase derived from a non-pathogenic microorganism.

The a-amylase may also be a fungal a-amylase, such as Fungamyl", which is available from Novo Nordisk.

The starch-hydrolysing enzyme may in another embodiment of the invention be a debranching enzyme, in particular a pullulanase 3.2.1.41), such as Promozyme".

WO 99/20239 PCT/DK98/00452 In a preferred embodiment the oral care composition comprises at least one starch-modifying enzyme as defined above, in particular a CGTase, and a mutanase and/or a dextranase.

In another preferred embodiment the oral care composition of the invention comprises at least one starch-hydrolysing enzyme as defined above, in particular a bacterial a-amylase, and a mutanase and/or a dextranase.

The mutanase may be derived from a strain of Trichoderma sp., in particular T.

harzianum, especially T. harzianum CBS 243.71 (available from Novo Nordisk).

The dextranase may be derived from a strain of Paecilomyces sp., in particular Paecilomyces lilacinus (available from Novo Nordisk).

In a second aspect the invention relates to an oral care product comprising an oral care composition of the invention.

An "oral care product" of the invention is defined as a product which can be used for maintaining and/or improving oral hygiene in the mouth of humans and animals, and/or preventing or treating dental diseases.

Examples of such oral care products include toothpastes, dental creams, gels or tooth powders, odontics, mouthwashes, denture cleaning agents, pre- or postbrushing rinse formulations, chewing gum and lozenges. An oral care product may also be in the form of a dental floss or toothpick.

Toothpastes and tooth gels typically include abrasive polishing materials, foaming agents, flavouring agents, humectants, binders, thickeners, sweeteners and water. As used herein, the term "toothpaste" is intended to refer to formulations in the form of both pastes and gels.

Mouthwashes typically comprise a water/alcohol solution, flavouring agents, humectants, sweeteners, foaming agents and colorants.

A chewing gum according to the invention may be prepared in a manner known per se by incorporating one or more enzymes into a conventional chewing gum base, e.g. based on chicle and/or one or more additional synthetic or natural polymers, and containing e.g. natural and/or artificial sweeteners, flavourings, etc. as desired. Upon addition of the enzyme(s) to the gum base, the temperature of the gum base should not be too high, e.g. preferably not more than about 60 0 C, more preferably not more than about 50 0

C.

Abrasive polishing materials for use in oral care products according to the invention include alumina and hydrates thereof, such as alpha alumina trihydrate, WO 99/20239 PCT/DK98/00452 6 magnesium trisilicate, magnesium carbonate, sodium bicarbonate ("baking soda"), kaolin, aluminosilicates, such as calcined aluminum silicate and aluminum silicate, calcium carbonate, zirconium silicate, and also powdered plastics, such as polyvinyl chloride, polyamides, polymethyl methacrylate, polystyrene, phenol-formaldehyde resins, melamine-formaldehyde resins, urea-formaldehyde resins, epoxy resins, powdered polyethylene, silica xerogels, hydrogels and aerogels and the like. Also suitable as abrasive agents are calcium pyrophosphate, water-insoluble alkali metaphosphates, dicalcium phosphate and/or its dihydrate, dicalcium orthophosphate, tricalcium phosphate, particulate hydroxyapatite and the like. It is also possible to employ mixtures of these substances.

Depending on the nature of the oral care product, the abrasive product may be present in an amount of from 0 to 70% by weight, preferably from 1% to 70%. For toothpastes, the abrasive material content typically lies in the range from 10% to by weight of the final toothpaste product.

Humectants are employed to prevent loss of water from e.g. toothpastes.

Suitable humectants for use in oral care products according to the invention include the following compounds and mixtures thereof: glycerol, polyol, sorbitol, polyethylene glycols (PEG), propylene glycol, 1,3-propanediol, 1,4-butane-diol, hydrogenated partially hydrolysed polysaccharides and the like. Humectants are in general present in an amount of from 0% to 80%, preferably 5 to 70% by weight in a toothpaste.

Examples of suitable thickeners and binders which help stabilize the dentifrice product are silica, starch, tragacanth gum, xanthan gum, extracts of Irish moss, alginates, pectin, cellulose derivatives, such as hydroxyethyl cellulose, sodium carboxymethyl cellulose and hydroxy-propyl cellulose, polyacrylic acid and its salts and polyvinyl-pyrrolidone. Thickeners may be present in toothpastes, creams and gels in an amount of from 0.1 to 20% by weight, and binders in an amount of from 0.01 to by weight of the final product.

As a foaming agent soap, anionic, cationic, non-ionic, amphoteric and/or zwitterionic surfactants can be used. These may be present at levels of from 0 to 15%, preferably from 0.1 to 13%, more preferably from 0.25 to 10% by weight of the final product.

Surfactants are only suitable in the context of the present invention to the extent that they do not exert any adverse effect on the activity of the enzymes.

WO 99/20239 PCT/DK98/00452 7 Examples of surfactants include fatty alcohol sulphates, salts of sulphonated monoglycerides or fatty acids having from 10 to 20 carbon atoms, fatty acid-albumin condensation products, salts of fatty acids amides and taurines and/or salts of fatty acid esters of isethionic acid.

Suitable sweeteners include saccharin and/or other sweeteners suitable for use in oral care products.

Flavouring agents, such as spearmint and peppermint, are usually present in low amounts, such as from 0.01% to about 5% by weight, especially from 0.1% to Water is usually added in an amount giving e.g. a toothpaste a flowable form, i.e. an amount of from 40% to 70% by weight of the final product.

In addition, water-soluble anti-bacterial agents, such as chlorhexidine digluconate, hexetidine, alexidine, quaternary ammonium anti-bacterial compounds and water-soluble sources of certain metal ions such as zinc, copper, silver and stannous ions zinc, copper and stannous chloride, and silver nitrate) may also be included.

Also contemplated according to the invention is the addition of other anticalculus agents, anti-plaque agents other than the enzymes which are the subject of the present application, compounds which can serve as a fluoride source, dyes/colorants, preservatives, vitamins, pH-adjusting agents, anti-caries agents, desensitizing agents, etc.

A toothpaste produced from an oral composition of the invention may e.g.

comprise the following ingredients (in weight of the final toothpaste composition): Abrasive material 10 to Humectant 0 to Thickener 0.1 to Binder 0.01 to Sweetener 0.1% to Foaming agent 0 to Starch-degrading enzyme(s) and/or starch-modifying enzyme(s) 0.0001 to Other enzymes 0 to Peroxide 0 to 1% A mouthwash produced from an oral care composition of the invention may e.g.

comprise the following ingredients (in weight of the final mouthwash composition): WO 99/20239 PCT/DK98/00452 8 0-20% Humectant 0-2% Surfactant Starch-degrading enzyme(s) and/or starch-modifying enzyme(s) Other enzymes 0-20% Ethanol 0-2% Other ingredients flavour, sweetener or other active ingredients such as fluorides).

0-70% Water The mouthwash composition may be buffered with an appropriate buffer, e.g.

sodium citrate or phosphate in the pH-range 6-7.5.

The mouthwash may be in non-diluted form to be diluted before use) or in diluted (ready-to-use) form.

The oral care compositions and products of the present invention can be made using methods which are common in the oral product field.

The invention further relates to the use of one or more starch-hydrolysing enzymes and/or one or more starch-modifying enzymes as described above for the preparation of a composition for the inhibition/prevention of plaque formation and/or removal of plaque.

An oral care product in solid to flowable form such as a toothpaste will typically be contacted with the teeth and/or gums using a toothbrush or the like. In the case of a liquid oral care product such as a mouthwash, the contact will typically take place by rinsing the mouth.

The time period during which an oral care product according to the invention is contacted with the teeth and/or gums to obtain the desired plaque inhibiting or plaque removing effect can vary according to such factors as the nature of the composition or product and the need of the subject. However, contacting the oral care product with the teeth and/or gums for between about 30 seconds to 15 minutes will normally be sufficient for obtaining the desired result, e.g. contact by brushing the teeth or rinsing the mouth for a period of about 1-3 minutes at a time. This is preferably performed on a regular basis, e.g. 1-3 times a day.

After use, the oral care product is typically removed from the mouth, e.g. by spitting it out, and the mouth may subsequently be rinsed with a liquid such as tap water.

WO 99/20239 PCT/DK98/00452 9 While not wishing to be bound by any particular theory, it is believed that the surprising plaque-inhibiting effect found according to the present invention may be due to the fact that the starch-hydrolysing and/or starch-modifying enzymes react with sucrose to produce a coupling sugar before enzymes produced by the microorganisms gain access to the sucrose. Regardless of the mechanism of action, the plaqueinhibiting effect observed by use of the enzymes in question is surprising and is not believed to have been described or suggested previously.

The invention will be further illustrated in the following non-limiting examples.

MATERIALS AND METHODS Materials Dextranase produced by Paecilomyces lilacinum (available from Novo Nordisk A/S).

Mutanase produced by Trichoderma harzianum CBS 243.71 (available from Novo Nordisk

A/S)

Maltogenase: Novamyl'" (a bacterial maltogenic a-amylase) available from Novo Nordisk

A/S.

Fungamyl (a fungal a-amylase) available from Novo Nordisk A/S.

Transglucosidase produced by Aspergillus niger (available from Amona Pharmaceuticals Co.).

BAN'" (a bacterial a-amylase) available from Novo Nordisk A/S.

CGTase produced by Thermobacterium sp., available from Novo Nordisk A/S.

Promozyme'" (a bacterial pullulanase) available from Novo Nordisk A/S Microorganisms Streptococcus sobrinus strain CBS 350.71 identifiable as OMZ 176 Actinomyces viscosus DSM 43329 Fusobacterium nucleatum subsp. polymorphum DSM 20482 Solutions Erythrosin B (Sigma) Equipment Chromameter CR-200 (Minolta) WO 99/20239 PCT/DK98/00452 Preparation of hydroxyapatite disks Hydroxyapatite (HA) disks are prepared by compressing 250 mg of hydroxyapatite in a disk die at about 5,900 kg (13,000 Ibs) of pressure for 5 minutes. The disks are then sintered at 600 0 C for 4 hours and finally hydrated with sterile deionized water.

Sterilisation of hvdroxyapatite disks HA disks are sterilised at 180 0 C for two hours.

Mutan preparation Mutan is prepared by growing Streptococcus sobrinus CBS 350.71 at pH 6.5, 37 0

C

(kept constant), and with an aeration rate of 75 rpm in a medium comprised of the following components: NZ-Case 6.5 g/l Yeast Extract 6 g/l

(NH

4 2

SO

4 20 g/l

K

2 PO4 3 g/l Glucose 50 g/l Pluronic PE6100 0.1 After 35 hours, sucrose is added to a final concentration of 60 g/l to induce glucosyltransferase. The total fermentation time is 75 hours. The supernatant from the fermentation is centrifuged and filtered (sterile). Sucrose is then added to the supernatant to a final concentration of 5% (pH is adjusted to pH 7.0 with acetic acid) and the solution is stirred overnight at 37 0 C. The solution is filtered and the insoluble mutan is harvested on Propex and washed extensively with deionized water containing 1% sodium benzoate, pH 5 (adjusted with acetic acid). Finally, the insoluble mutan is lyophilized and ground.

Determination of dextranase activity (KDU} One Kilo Novo Dextranase Unit (1 KDU) is the amount of enzyme which breaks down dextran forming reducing sugar equivalent to 1 g maltose per hour in the Novo Nordisk method for determination of dextranase based on the following standard conditions: WO 99/20239 PCT/DK98/00452 11 Substrate Dextran 500 (Pharmacia) Reaction time 20 minutes Temperature 40 0

C

pH 5.4 A detailed description of Novo Nordisk's analytical method (AF 120) is available on request.

Determination of mutanase activity (MU) One Mutanase Unit (MU) is the amount of enzyme which under standard conditions liberates 1 lmol reducing sugar (calculated as glucose) per minute.

Standard Conditions Substrate 1.5% mutan Reaction time 15 minutes Temperature pH A detailed description of Novo Nordisk's analytical method (AF 180/1-GB) is available from Novo Nordisk A/S on request.

Determination of BAN" (Bacterial Amvlase Novo) activity (KNU) (Kilo Novo-a-amvlase Units) The standard activity is determined relative to an analytical standard under the following conditions: Substrate: p-nitrophenyl-alpha-D-maltoheptaoside (pNP-G7) Temperature: 37 0

C

pH: 7.1 A detailed description of Novo Nordisk's analytical method (Novo Nordisk publication AF215) is available on request.

Determination of Fungamyl® activity (FAU) One Fungal a-amylase Unit (1 FAU) is the amount of enzyme which breaks down 5.26 g starch (Merck, Amylum solubile Erg. B.6, Batch 9947275) per hour at Novo Nordisk's standard method for determination of a-amylase based upon the following standard conditions: WO 99/20239 PCT/DK98/00452 12 Substrate: soluble starch Reaction time: 7-20 minutes Temperature 37 0

C

pH: 4.7 A detailed description of Novo Nordisk's method of analysis is available on request.

Determination of Maltoqenase activity (MANU) 1 Maltogenic Amylase Novo Unit (MANU) is defined as the amount of enzyme which under standard conditions hydrolyzes 1 mole of maltotriose per minute. Copies of the analytical method are available on request.

Determination of AMG'" activity (AGU) One Novo Amyloglucosidase Unit (AGU) is defined as the amount of enzyme which hydrolyzes 1 (tmole maltose per minute under the following standard conditions: Substrate: maltose Temperature: 25 0

C

pH 4.3 (acetate buffer) Reaction time 30 minutes A detailed description of the analytical method (AF 22) is available on request.

Determination of Translucosidase activity (AGU) Transglucosidase activity is determined using the method described above for determining AMGTM activity, and is expressed using the same units (AGU).

Determination of CGTase activity (KNU) The CGTase KNU enzymatic activity was measured by a slightly modified procedure of the Phadebas amylase test (Pharmacia). Phadebas tablets (Phadebas'" Amylase Test, Pharmacia) are used as a substrate. This substrate is a cross-linked insoluble blue-colored starch polymer, which is mixed with bovine serum albumin and a buffer substance. After suspension in water, starch is hydrolyzed by the enzyme, thereby yielding blue fragments. The determination is carried out after incubation at 60 0 C, pH 6.2, in 0.15 nM calcium for 15 minutes. The absorbance of the resulting blue solution, determined at 620 nm, corresponds to the enzymatic activity.

WO 99/20239 PCT/DK98/00452 13 The enzyme activity is compared to that of an enzyme standard, and the activity is expressed in the same unit as that of the enzyme standard. The enzyme standard was Termamyl T M (Novo Nordisk A/D, Denmark), the amylolytic activity of which has been be determined using potato starch as a substrate. This method is based on the break-down of modified potato starch by the enzyme, and the reaction is followed by mixing samples of the starch/enzyme solution with an iodine solution. Initially, a blackish-blue color is formed, but during the break-down of the starch the blue color gets weaker and gradually turns into a reddish-brown, which is compared to a colored glass standard.

One Kilo Novo a-Amylase Unit (KNU) is defined as the amount of enzyme which, under standard conditions at 37 0 C 0.05; 0.0003 M Ca2+; and pH 5.6) dextrinizes 5.26 g starch dry substance, Merck Amylum soluble. The activity is expressed below in Novo Units (NU) per ml.

CGTase activity was determined by incubating diluted enzyme with substrate in mM sodium citrate, pH 6.0 for 4-10 minutes at 60 0

C.

Determination of Promozyme" activity (PUN) One Pullulanse Unit Novo (PUN) is defined as the amount of enzyme which hydrolyzes pullulan, liberating reducing carbohydrate with a reducing carbohydrate with a reducing power equivalent to 1 pmole glucose per minute under the following standard conditions: Substrate: 0.2% pullulan Temperature: 40 0

C

pH: 5.0 (0.05M citrate buffer) Reaction time: 30 minutes A detailed description of the analysis method (AF190) is available on request.

Assessment of the plaue inhibition effect The method used for assessing the plaque removal effect is based on the method described by Kao in JP 2250816. According to the present method, hydroxyapatite disks, sterilised as described above, become coated with a biofilm by being placed overnight in the presence of three strains of oral microorganisms (Streptococcus sobrinus, Actinomyces viscosus and Fusobacterium nucleatum) and various enzymes in a Brain Heart Infusion Medium (Difco) containing 0.2% sucrose.

WO 99/20239 PCT/DK98/0W25 14 To test plaque inhibition effect, 0.1% Erythrosin B in PBS (phosphate buffered saline) is used to stain plaque present on the hydroxyapatite disks red. The intensity of the red colour (referred to as is measured on a Chromameter CR-200. The maximum a* value is 60. Values below that indicate a less intensive red colour (i.e.

less plaque present). An a* value of zero indicates no red colouring no plaque). A plaque inhibition effect is expressed as a relative figure based on the value of a* for a non-treated biofilm being 100%.

EXAMPLES

Example 1 Plague preventing effect of different starch-hvdrolvsing enzymes Three oral microorganisms, Streptococcus sobrinus, Actinomyces viscosus and Fusobacterium nucleatum, respectively, were cultivated anaerobically overnight at 37°C in the presence of various enzymes. Hydroxyapatite disks coated with sterilised saliva were immersed in a culture broth during cultivation so that an oral biofilm was formed on the disks. After cultivation, the disks were briefly rinsed with a phosphate buffered saline and then incubated in a 1 ml 0.1 Erythrosin B in PBS for 1 minute to stain plaque present on the hydroxyapatite disks red. The Erythrosin B solution was removed and the disks were rinsed with PBS for a few minutes. The disks were airdried overnight. The intensity of the red colour was measured on a Chromameter CR-200 and compared to that of the non-treated disks.

The plaque-prevention results of a number of different enzymes are shown below in Table 1.

WO 99/20239 PCT/DK98/00452 Table 1: Plaque inhibiting/preventing activity of selected starch-hydrolysing enzymes Enzyme Activity Plaque intensity None (control) 100 Maltogenase" (bacterial 200 MANU/ml 36.8** maltogenic a-amylase) Fungamyl" 40 FAU/ml 45.3** (fungal a-amylase) Transglucosidase 32 AGU/ml 54.2 derived from A. niger Promozyme" (bacterial 10 PUN/ml 45.0* pullulanase) statistically significant, p 0.01 statistically significant, p 0.001 As can be seen in the table above, statistically significant plaque prevention/inhibition effects are obtained with all starch-hydrolysing enzymes at the activity levels listed.

Example 2 Plaque preventing effect of a starch-hydrolysing enzyme, a starch-modifying enzyme in combination with a mutanase and a dextranase Three oral microorganisms, Streptococcus sobrinus, Actinomyces viscosus and Fusobacterium nucleatum, respectively, were cultivated anaerobically overnight at 37 0 C in the presence of 1 MU/ml mutanase and 1 KDU/ml dextranase and the enzyme listed in the Table below. Hydroxyapatite disks coated with sterilised saliva were immersed in a culture broth during cultivation so that an oral biofilm was formed on the disks. After cultivation, the disks were treated as describe in Example 1, and the intensity of the red colour was determined.

WO 99/20239 PCT/DK98/00452 16 Table 2: Plaque inhibiting/preventing activity of a starch-modifying enzyme and a starch-hydrolysing enzyme together with mutanase and dextranase Enzyme Activity Plaque intensity Control* 100 BAN'" (Bacterial 12 KNU/ml 42.7 a-amylase) CGTase 0.32 KNU/ml 40.4 All culture broths contained 1 MU/ml mutanase and 1 kDU/ml dextranase As can be seen, the use of the two enzymes BAN TM and the CGTase together with a mutanase and a dextranase resulted in an improved plaque inhibition compared to mutanase and dextranase alone. The additional effect of the combination with mutanase and dextranase was particularly pronounced for CGTase. For both BANTM and CGTase, there was a synergistic effect of combining them with mutanase and dextranase, since use of BANTM or CGTase alone did not provide a plaque reduction in this test.

Example 3 Enzyme protein dose response curves for plaque inhibition/prevention effect Three oral microorganisms, Streptococcus sobrinus, Actinomyces viscosus and Fusobacterium nucleatum, respectively, were cultivated anaerobically overnight at 37 0 C in the presence of various enzymes (FungamylTM, PromozymeTM and Maltogenase T M all from Novo Nordisk Hydroxyapatite disks coated with sterilised saliva were immersed in a culture broth during cultivation so that an oral biofilm was formed on the disks. After cultivation, the disks were briefly rinsed with a phosphatebuffered saline and then incubated in a 1 ml 0.1% Erythrosin B solution in PBS for 1 minute to stain plaque present on the hydroxyapatite disks red. The Erythrosin B solution was removed and the disks were rinsed with PBS for a few minutes. The disks were air-dried overnight. Biofilm remaining on the disks was determined by measuring the intensity of the red colour using a Chromameter CR-200, the obtained values being compared to values for non-treated disks. The results are shown in the attached Figures 1, 2 and 3.

Claims

1. An oral care composition comprising a plaque-inhibiting and/or plaque- removing effective amount of at least one starch-modifying enzyme selected from the group of enzymes within E.C. 2.4.1.

2. The oral care composition according to claim 1, wherein the starch-modifying enzyme is a CGTase.

3. The oral care composition according to claim 2, wherein the CGTase is derived from a strain of Bacillus autolyticus, a strain of Bacillus cereus, d strain of Bacillus circulans, .a strain of Bacillus circulans var. alkalophilus, a strain of Bacillus coagulans, a strain of Bacillus firmus, a strain of Bacillus halophilus, a strain of Bacillus macerans, a strain of Bacillus megaterium, a strain of Bacillus ohbensis, a strain of Bacillus stearothermophilus; a strain of Bacillus subtilis, a strain of Klebsiella pneumoniae, a strain of Thermoanaerobacter sp., a strain of Thermoanaerobacter ethanolicus, a strain of Thermoanaerobacter finnii, a strain of Clostridium thermoamylolyticum, a strain of Clostridium thermosaccharolyticum, or a strain of Thermoanaerobacterium thermosulfurigenes.

4. The oral care composition according to claim 1, wherein the starch-modifying *enzyme is a branching enzyme within E.C. 2.4.1.18.

5. The oral care composition according to claim 4, wherein the branching 20 enzyme is derived from Aspergillus niger.

6. The oral care composition according to any one of claims 1-5, further comprising at least one starch-hydrolysing enzyme.

7. The oral care composition according to claim 6, wherein the starch- hydrolysing enzyme is an a-amylase. 25 8. The oral care composition according to claim 7, wherein the ca-amylase is a bacterial a(-amylase.

9. The oral care composition according to claim 7 or 8, wherein the ca-amylase is selected from a-amylases derived from Bacillus subtilis; a-amylases derived from Bacillus amyloliquefaciens; ca-amylases derived from Bacillus stearothermophilus; a-amylases derived from Aspergillus oryzae; and a-amylases derived from non- pathogenic microorganisms. The oral care composition according to claim 7, wherein the ca-amylase is a fungal a-amylase. [R:\LIBXX] 20116spec.doc:gcc 18

11. The oral care composition according to claim 6, wherein the starch- hydrolysing enzyme is a debranching enzyme, in particular a pullulanase.

12. The oral care composition according to any one of claims 1-11, further comprising a dextranase and/or a mutanase.

13. The oral care composition according to claim 12, wherein the mutanase is derived from Trichoderma harzianum, and/or the dextranase is derived from a strain of Paecilomyces.

14. An oral care product comprising an oral care composition according to any one of claims 1-13.

15. The oral care product of claim 14 which is in the form of a toothpaste, a tooth gel, a tooth powder, a mouthwash, a denture cleaning composition, a chewing gum, a lozenge, a dental floss or a toothpick.

16. Use of at least one starch-modifying enzyme selected from the group of enzymes within E.C. 2.4.1. for the preparation of an oral care composition for the inhibition of plaque formation and/or removal of plaque.

17. Use according to claim 16, where the starch-modifying enzyme is as defined in any one of claims J. 18. Use of at least one starch-modifying enzyme selected from the group of 0. enzymes within E.C. 2.4.1. in combination with at least one starch-hydrolysing enzyme 20 for the preparation of an oral care composition for the inhibition of plaque formation and/or removal of plaque.

19. Use according to claim 18, where the starch-hydrolysing enzyme is as defined in any one of claims 7-11.'

20. An oral care composition as defined in any one of claims 1 to 13, wherein a 25 plaque-inhibiting effective amount of said starch-modifying enzyme is present in said composition.

21. An oral care composition as defined in any one of claims 1 to 13, wherein a plaque-removing effective amount of said starch-modifying enzyme is present in said composition and said composition is a plaque-removing composition.

22. An oral care composition as defined in any one of claims 1 to 13, wherein a plaque-inhibiting and a plaque-removing effective amount of said starch-modifying enzyme is present in said composition and said composition is a plaque-inhibiting S composition. [R:\LIBX]j201 I6specdoc:gcc 19

23. A method of inhibiting plaque and/or removing plaque from the teeth of a subject comprising contacting said teeth with the oral care composition of any one of claims 1-13.

24. An oral care composition as defined in claim 1 wherein the starch-modifying enzyme is substantially as herein described with reference to Example 1. An oral care composition as defined in claim 1 wherein the starch-modifying enzyme is a CGTase substantially as herein described with reference to Example 2 and the composition further includes a bacterial a-amylase substantially as herein described with reference to Example 2.

26. Use of a starch-modifying enzyme substantially as herein described with reference to Example 1, for the preparation of an oral care composition for the inhibition of plaque formation and/or removal of plaque.

27. Use of a starch-modifying enzyme wherein the starch-modifying enzyme is a CGTase substantially as herein described with reference to Example 2 in combination with a bacterial a-amylase substantially as herein described with reference to Example 2, for the preparation of an oral care composition for the inhibition of plaque formation and/or removal of plaque.

28. An oral care composition as defined in any one of claims 1 to 13, 24 or when used to inhibit or remove plaque from the teeth of a subject. Dated 19 April, 2001 o Novozymes A/S Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON (R:\LIBXX]2011 6spcc.doc:gcc